Vanqua Bio

Vanqua Bio is a private biopharmaceutical company headquartered in Chicago, Illinois, in the United States. Founded in 2019, the company is focused on discovering and developing next-generation medicines for neurodegenerative diseases. Its stated mission is to deliver medicines that transform the lives of patients with neurodegenerative diseases, and it describes its overall aim as "vanquishing neurodegeneration." The company combines advanced insights into critical neuronal cell pathways with cutting-edge assays to advance needed therapies. Vanqua Bio's scientific approach harnesses leading-edge knowledge of lysosomal biology and the innate immune system, together with a screening platform that uses patient iPSC-derived neuronal cells and proven drug discovery and development expertise. The company states that this approach is intended to deliver first-in-class and best-in-class therapies to slow or stop the progression of Parkinson's disease (PD), Alzheimer's disease (AD) and related neurological diseases. The company's lead program targets glucocerebrosidase (GCase) as a potential treatment for Parkinson's disease and Dementia with Lewy Bodies (DLB). This program is built on the genetic association between the GBA1 gene, which encodes GCase, and the lysosomal dysfunction that occurs in Parkinson's disease (GBA-PD). Mutations in GBA1 are described by the company as the most common genetic risk factor for PD, with roughly 10% of patients with PD in the United States and Europe carrying a GBA1 mutation. Additional Vanqua Bio programs address overactivation of the innate immune system in central and peripheral disorders, including Alzheimer's disease. Vanqua Bio has assembled a leadership team, board of directors and scientific advisors with experience in neuroscience research and drug development. The leadership team is led by Chief Executive Officer Jim Sullivan, Ph.D., alongside Chief Scientific Officer Kevin Hunt, Ph.D., Chief Medical Officer Maurizio Facheris, M.D., and Chief Business Officer Jack Beyer, among others. The board includes representatives of life-science investors such as OrbiMed, Avoro Ventures and Omega Funds, and the company states that its investors and partners are committed leaders in Parkinson's disease, neuroscience research and life-science investments. As a privately held, clinical-stage-oriented biopharmaceutical company, Vanqua Bio operates primarily in the United States and is backed by specialist life-science investors rather than being publicly listed. Its pipeline is centered on disease-modifying approaches for neurodegenerative conditions with significant unmet need.

Vanqua Bio was founded in 2019 as a biopharmaceutical company focused on discovering and developing next-generation medicines for neurodegenerative diseases. From its base in Chicago, Illinois, the company set out to build a neuroscience-focused organization combining insights into critical neuronal cell pathways with cutting-edge assays. The company's scientific foundation rests on two connected areas of biology: lysosomal function and the innate immune system. Its lead program targets glucocerebrosidase (GCase), an enzyme encoded by the GBA1 gene, as a potential treatment for Parkinson's disease (PD) and Dementia with Lewy Bodies (DLB). Mutations in GBA1 are described by the company as the most common genetic risk factor for PD; roughly 10% of patients with PD in the United States and Europe carry a GBA1 mutation, and such individuals often develop PD at a younger age and show more rapid disease progression than patients with idiopathic PD. In patients with PD, mutations in one copy of the GBA1 gene can decrease GCase activity by up to 50%, and the magnitude of that decrease is strongly associated with symptom severity. Decreased GCase activity is also observed in idiopathic PD and Lewy Body Dementia. Because functional GCase is crucial for the recycling and disposal of proteins and lipids in the lysosome, GCase mutations can trigger lysosomal dysfunction, cell toxicity, inflammation and accumulation of alpha synuclein, a hallmark of PD. Beyond its GCase program, Vanqua Bio has pursued additional programs addressing overactivation of the innate immune system in central and peripheral disorders, including Alzheimer's disease. The company's platform uses patient iPSC-derived neuronal cells for screening, which it combines with drug discovery and development expertise to pursue first-in-class and best-in-class therapies intended to slow or stop disease progression. To support this work, Vanqua Bio assembled a leadership team, board of directors and scientific advisors with experience in neuroscience research and drug development. The leadership team includes CEO Jim Sullivan, Ph.D., Chief Scientific Officer Kevin Hunt, Ph.D., Chief Medical Officer Maurizio Facheris, M.D., and Chief Business Officer Jack Beyer. The board of directors includes representatives of life-science investors such as OrbiMed, Avoro Ventures and Omega Funds, reflecting the company's backing by specialist investors in Parkinson's disease, neuroscience research and life-science investment. Scientific advisors include Dimitri Krainc, Gregory Grabowski, Kalpana Merchant and James B. Summers. As of the company's own communications, Vanqua Bio remains an active, privately held biopharmaceutical company headquartered in Chicago, focused on advancing its pipeline of disease-modifying therapies for neurodegenerative diseases.

• 2019

  Vanqua Bio is founded as a biopharmaceutical company focused on neurodegenerative diseases.

• Company advances a lead program targeting glucocerebrosidase (GCase) for Parkinson's disease and Dementia with Lewy Bodies.

• Vanqua Bio develops additional programs addressing innate immune system overactivation in central and peripheral disorders, including Alzheimer's disease.

A private, neuroscience-focused biopharmaceutical company developing first-in-class and best-in-class disease-modifying therapies for neurodegenerative diseases, built on lysosomal biology, innate immunology and patient iPSC-derived neuronal cell screening.

• GCase program (GBA Parkinson's disease)

  Lead program targeting glucocerebrosidase (GCase) as a potential treatment for Parkinson's disease and Dementia with Lewy Bodies, based on the GBA1 gene association and lysosomal dysfunction.

• Innate immune system programs

  Additional programs addressing overactivation of the innate immune system in central and peripheral disorders, including Alzheimer's disease.

1. 1Home Page - Vanqua Biovanquabio.com
2. 2About Us - Vanqua Biovanquabio.com
3. 3Science & Pipeline - Vanqua Biovanquabio.com
4. 4Vanqua Bio (United States) - Wikidatawikidata.org